Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2025-12-24 @ 5:04 PM
NCT ID:
NCT02490150
Eligibility Criteria:
Inclusion Criteria:
* Women 18-35 y old ,with regular spontaneous menstrual cycles of 25-30 days length
* Who had vaginal sexual intercourse or have no inconvenient for vaginal explorations
* Donors can´t have more than 6 children (neither own or after donations)
* Not be adopted or being born after a gamete donation pregnancy
* BMI between 18-28 kg/m2
* Height \> 1.55cm
* Gynecological and general examination with Pap smear, HIV, HCV (hepatitis C virus ), HBV (hepatitis B virus ) and RPR(rapid plasma reagin test ) negative serology, and with normal karyotype
* No abnormal Psychological profile
* Discard any disease: blood disorders, neurodegenerative/psychiatric diseases, Fragile X Syndrome, cystic fibrosis carrier, oncology diseases.
* Without psychological/psychiatric family history
* Will conform to the protocol for the duration of the study
* Willingness of adhesion to protocol during the whole study period
* Signed informed consent
Exclusion Criteria:
* Polycystic ovarian syndrome
* Antral follicle count \> 20
* Hypersensitivity to the active substance or any of the excipients
* Abnormal vaginal bleeding of unknown ethiology
* Presence of ovarian cysts or increased size ovaries
* History of ovarian hyperstimulation syndrome
* Previous controlled ovarian stimulation cycle with more than 30 follicles ≥ 11mm
* Previous abdominal surgery that contraindicated the practice of follicular puncture
* HIV, HCV, HBV positive serology in women or partner
* Important systemic diseases that could interfere with gonadotrophin treatment (ovarian and hypothalamic tumors…)
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
35 Years
Study:
NCT02490150
Study Brief:
Protocol Section:
NCT02490150